Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool November 13, 2006 Brian Lawler	King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.
The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool February 27, 2004 Zeke Ashton	King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool March 1, 2007 Brian Lawler	King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter.
The Motley Fool October 30, 2009 Brian Orelli	It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
PC Magazine September 21, 2004	Age of Empires II: The Age of Kings The king of real-time strategy games has yet to be dethroned.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
Pharmaceutical Executive June 1, 2006 Sara Calabro	King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool January 30, 2007 Rick Aristotle Munarriz	The King Gives Investors Bread and Circus If Burger King keeps growing with its franchisees as happy as The King himself, royalties will be even more generous. Investors, take note.
The Motley Fool March 21, 2011 Jim Royal	Meet the Cash Kings of Drilling Check out Transocean, the cash king of the drilling sector.
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
The Motley Fool November 5, 2007 Brian Orelli	Last Look at Mini-Mylan An impending merger with Merck's KGaA's generic drug business should more than double revenue at Mylan.
Chemistry World May 1, 2015 Rebecca Trager	Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
Fast Company Pavithra Mohan	Activision To Buy Candy Crush Creator For $5.9 Billion Activision Blizzard, the company behind video games like Call of Duty and World of Warcraft, just inked a deal to acquire King Digital Entertainment, the maker of wildly popular mobile game Candy Crush Saga.
The Motley Fool July 30, 2007 Brian Orelli	Mega Mylan Is on Track Comparing year-over-year results for Mylan will continue to be complicated for the next year and a half or so. It's one merger down, one to go for the generic drug company. Investors, take note.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
BusinessWeek September 18, 2006 Gene G. Marcial	Now, Burger King Looks More Appetizing Burger King leaped out of the frying pan into the fire in early August when it reported disappointing results for its fourth quarter ended June 30.
The Motley Fool January 12, 2006 Rich Duprey	Will the SEC Trim the Hedges? As hedge funds are immersing themselves even more in mergers and acquisitions, a field that is fast approaching $1 trillion a year, it's not surprising that they will now also find themselves under closer scrutiny by regulators.
The Motley Fool February 28, 2008 Brian Orelli	Mylan Almost Triples Revenue -- Big Deal Mylan's growth seems impressive last year, but that growth was all extrinsic, and it came at a cost.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool October 31, 2008 Brian Orelli	A Generic McMansion Mylan took an awfully big bite when it purchased Merck KGaA's generic-drug business last year, but so far it's proven that it can handle it.
Inc. June 15, 2000 Anne Marie Borrego	Supplies on Demand Problem: Managing office-supply inventory and purchases Solution: A Web site that does it all Payoff: Cost savings, fewer headaches
Salon.com February 19, 2002 Richard Blow	The chill is gone The once-great Stephen King has been recycling his plots and characters for 20 years now. It's time he made good on his threats to retire...
Bank Systems & Technology August 16, 2010 Matt Gunn	Customer-Centered Banking is the Future, Author Says Brett King discusses his book Bank 2.0 and the future of banking.
The Motley Fool May 12, 2008 Brian Orelli	Merging Mylan Meanders Through 2008 In the larger-is-better world of generic-drug makers, it's kind of surprising that investors haven't yet gotten behind the Mylan/Merck KGaA deal.
The Motley Fool October 5, 2006 Rick Aristotle Munarriz	The King Wants to Play Burger King believes that Xbox marks the spot of opportunity. The Burger King-branded games will either be marketing genius or a classic blunder. Investors, take note.
The Motley Fool February 7, 2007 Brian Lawler	Mylan Adjusts to the Matrix The drugmaker got a bump from a new generic and settles in with its Matrix acquisition. Investors, take note.
The Motley Fool December 6, 2010 Seth Jayson	Why the Street Should Love King Pharmaceuticals' Earnings Over the past 12 months, King Pharmaceuticals generated $276.2 million in FCF on net income of $83.9 million. That means it turned 17.6% of its revenue into FCF. That sounds pretty impressive.
Registered Rep. February 7, 2012 Jerry Gleeson	Morgan Stanley Smith Barney's King Breaks Away, Taps Dynasty for Help A Morgan Stanley Smith Barney team led by Larry King in Saratoga Springs, N.Y. left the wirehouse and started an independent registered investment advisor, King Wealth Management Group.
The Motley Fool August 27, 2009 Rob Plaza	Send This Restaurant Stock Back Investors are excited about Burger King, but that likely won't last.
Chemistry World April 13, 2015 Emma Stoye	Generics giant Mylan offers $30 billion for Perrigo Generics manufacturer Mylan has made an unsolicited, public offer to buy Ireland-based rival Perrigo for $205 per share.
Salon.com July 20, 2000 Gary Kaufman	Shocking allegation It seems that Don King may have acted improperly.
Salon.com July 11, 2000 Seth Mnookin	Sharps & Flats God and the King meet again. The result: Bloodless background music.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
AskMen.com Brandon Dyce	Sean John I AM KING Sean Combs' latest fragrance looks to change all the rules, and I AM KING is sexy, smooth and spot-on.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
The Motley Fool August 27, 2007 Lawrence Rothman	Don't Overthrow the King Yet Despite reporting a quarterly profit, shares of Burger King dropped, perhaps because of investor concerns about what the fast-food chain can do next that it hasn't already done.
Salon.com July 26, 2000 Andrew Essex	I stole from Stephen King The honor system? I don't think so.
BusinessWeek July 22, 2010	Hard Choices: Larry King As Larry King Live nears the end of its run, the king of talk remembers his decision to stick with CNN.
The Motley Fool April 17, 2006 Jim Mueller	Whither Goest Thou, Mr. Brenneman? Greg Brenneman joins a long line of short-term CEOs at Burger King, shortly before its IPO. Would-be investors need to give serious consideration to this sudden change at the top, and the company's increasing difficulty in keeping a long-term CEO.
The Motley Fool September 4, 2008 Brian Orelli	Tapping the Brakes on the Teva-Barr Deal The FTC wants more information on this pharma merger before it offers its approval.
Financial Planning August 1, 2009 Jim Grote	Domestic Affairs Elaine King prepares her divorcee clients for (1) financial independence; (2) a well-planned estate; and (3) a family that is competent and comfortable with wealth.
The Motley Fool December 5, 2008 Rich Smith	This Just In: Upgrades and Downgrades Citigroup, after a year of no information on restaurant stocks, suddenly downgrades Domino's, McDonald's, and Yum! Brands.